PE03722016A1 - Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation - Google Patents

Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation

Info

Publication number
PE03722016A1
PE03722016A1 PE2016000025A PE0000252016A PE03722016A1 PE 03722016 A1 PE03722016 A1 PE 03722016A1 PE 2016000025 A PE2016000025 A PE 2016000025A PE 0000252016 A PE0000252016 A PE 0000252016A PE 03722016 A1 PE03722016 A1 PE 03722016A1
Authority
PE
Peru
Prior art keywords
anticholinergic
corticosteroid
inhalation
dry powder
powder formulation
Prior art date
Application number
PE2016000025A
Other languages
Spanish (es)
Inventor
Azita Askey-Sarvar
Francesca Schiaretti
Irene Pasquali
Rossella Musa
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to EP13176114 priority Critical
Priority to EP13194763 priority
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of PE03722016A1 publication Critical patent/PE03722016A1/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51292914&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE03722016(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00Inhalators
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/958Drug, bio-affecting and body treating compositions for smoking or inhaling

Abstract

Formulacion en polvo seco para inhalacion que comprende una combinacion de un anticolinergico, un agonista de adrenoceptor beta2 de accion prolongada y un corticosteroide; Dry powder formulation for inhalation comprising a combination of an anticholinergic, beta2-adrenoceptor agonist long acting and a corticosteroid; proceso de preparacion y usos terapeuticos de la misma process preparation and therapeutic uses thereof
PE2016000025A 2013-07-11 2014-07-10 Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation PE03722016A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP13176114 2013-07-11
EP13194763 2013-11-28

Publications (1)

Publication Number Publication Date
PE03722016A1 true PE03722016A1 (en) 2016-05-19

Family

ID=51292914

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000025A PE03722016A1 (en) 2013-07-11 2014-07-10 Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation

Country Status (28)

Country Link
US (2) US9402825B2 (en)
EP (2) EP3409270A1 (en)
JP (1) JP6426167B2 (en)
KR (1) KR20160029797A (en)
CN (1) CN105338960B (en)
AU (1) AU2014289185B2 (en)
CA (1) CA2917752A1 (en)
CL (1) CL2016000028A1 (en)
DK (1) DK3019153T3 (en)
EA (1) EA029125B1 (en)
ES (1) ES2699986T3 (en)
GE (1) GEP20186853B (en)
HK (1) HK1218712A1 (en)
HR (1) HRP20182008T1 (en)
HU (1) HUE039827T2 (en)
IL (1) IL243507D0 (en)
LT (1) LT3019153T (en)
MX (1) MX2016000290A (en)
PE (1) PE03722016A1 (en)
PH (1) PH12016500043A1 (en)
PL (1) PL3019153T3 (en)
RS (1) RS57799B1 (en)
SG (1) SG11201600110RA (en)
SI (1) SI3019153T1 (en)
TN (1) TN2016000007A1 (en)
TW (1) TWI642450B (en)
UA (1) UA116907C2 (en)
WO (1) WO2015004243A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170040392A (en) * 2009-12-23 2017-04-12 키에시 파르마슈티시 엣스. 피. 에이. Combination therapy for Copd
MY165888A (en) * 2012-01-25 2018-05-18 Chiesi Farm Spa Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
PE03722016A1 (en) * 2013-07-11 2016-05-19 Chiesi Farma Spa Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation
US9554992B2 (en) 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
JP2016189160A (en) * 2015-03-30 2016-11-04 ブラザー工業株式会社 Display control device, display control method, and storage medium
CN107666903A (en) * 2015-05-01 2018-02-06 得克萨斯州大学系统董事会 Multidrug brittle matrix compositions
KR20180082443A (en) 2015-11-16 2018-07-18 키에시 파르마슈티시 엣스. 피. 에이. Method for the preparation of a dry powder formulation comprising an anticholinergic agent, a corticosteroid and a beta-adrenergic drug
SG11201804048WA (en) 2015-11-16 2018-06-28 Chiesi Farm Spa A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
WO2018206618A1 (en) 2017-05-11 2018-11-15 Chiesi Farmaceutici S.P.A. A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
WO2018206619A1 (en) 2017-05-11 2018-11-15 Chiesi Farmaceutici S.P.A. A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
WO2019060595A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. Dry powder inhalable medicament comprising glycopyrronium

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL200941B1 (en) * 1998-11-13 2009-02-27 Jagotec Ag Dry powder for inhalation
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
EP2283817B1 (en) * 2000-11-30 2016-05-18 Vectura Limited Method of making particles for use in a pharmaceutical composition
PE12272001A1 (en) * 2000-04-17 2002-01-07 Chiesi Farma Spa Pharmaceutical formulations for DPIs in the form of hard agglomerates
CA2413692C (en) * 2000-06-27 2011-10-18 Vectura Limited Method of making particles for use in a pharmaceutical composition
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
ES2262730T3 (en) 2002-07-31 2006-12-01 Chiesi Farmaceutici S.P.A. Powder inhaler.
JO3102B1 (en) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A Pharmaceutical formulations for dry powder inhalers comprising a low- dosage strength active ingredient
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1944018A1 (en) * 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
BR112012015334A2 (en) 2009-12-23 2016-03-15 Chiesi Farma Spa Combination therapy for chronic obstructive pulmonary disease
KR20170040392A (en) * 2009-12-23 2017-04-12 키에시 파르마슈티시 엣스. 피. 에이. Combination therapy for Copd
TR201000681A2 (en) 2010-01-29 2011-08-22 Bilgiç Mahmut dry powder formulations for inhaled aerosol.
CA2794941C (en) * 2010-04-01 2018-05-15 Chiesi Farmaceutici S.P.A. Process for preparing carrier particles for dry powders for inhalation
SI2560611T1 (en) * 2010-04-21 2018-03-30 Chiesi Farmaceutici S.P.A. "process for providing particles with reduced electrostatic charges"
CA2803418A1 (en) * 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising an antimuscarinic drug
MY165888A (en) * 2012-01-25 2018-05-18 Chiesi Farm Spa Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
PE03722016A1 (en) * 2013-07-11 2016-05-19 Chiesi Farma Spa Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation

Also Published As

Publication number Publication date
HUE039827T2 (en) 2019-02-28
SG11201600110RA (en) 2016-02-26
JP2016523950A (en) 2016-08-12
HRP20182008T1 (en) 2019-01-25
PH12016500043A1 (en) 2016-03-28
HK1218712A1 (en) 2017-03-10
JP6426167B2 (en) 2018-11-21
MX2016000290A (en) 2016-04-13
US9808422B2 (en) 2017-11-07
KR20160029797A (en) 2016-03-15
EP3019153B1 (en) 2018-09-05
EA201690006A1 (en) 2016-07-29
US20160263027A1 (en) 2016-09-15
EP3409270A1 (en) 2018-12-05
CA2917752A1 (en) 2015-01-15
GEP20186853B (en) 2018-05-25
LT3019153T (en) 2018-11-26
AU2014289185A1 (en) 2016-02-04
IL243507D0 (en) 2016-02-29
TWI642450B (en) 2018-12-01
AU2014289185B2 (en) 2019-05-23
CN105338960A (en) 2016-02-17
SI3019153T1 (en) 2018-12-31
CN105338960B (en) 2019-06-04
PL3019153T3 (en) 2019-02-28
US20150017248A1 (en) 2015-01-15
ES2699986T3 (en) 2019-02-13
CL2016000028A1 (en) 2016-08-05
DK3019153T3 (en) 2018-11-19
US9402825B2 (en) 2016-08-02
TW201536352A (en) 2015-10-01
UA116907C2 (en) 2018-05-25
WO2015004243A1 (en) 2015-01-15
TN2016000007A1 (en) 2017-07-05
RS57799B1 (en) 2018-12-31
EP3019153A1 (en) 2016-05-18
EA029125B1 (en) 2018-02-28
PH12016500043B1 (en) 2016-03-28

Similar Documents

Publication Publication Date Title
CR20140512A (en) Devices and methods for producing additives implant components
RU2015146869A (en) based on nicotine salts Formulations for aerosol devices and methods for their use
BR112013023175A2 (en) compound, inhibitor, drug, anticancer agent, pharmaceutical composition, method for treating cancer, and use of a compound
UY35351A (en) stable aqueous formulations of adalimumab
AR091700A1 (en) Antibodies and immunoconjugates anti-CD79b
BR112013027119A2 (en) new linker-drug conjugates (ADCs) and use thereof
GT201500063A (en) therapeutic nanoparticles comprising a therapeutic agent and methods to perform them and use
CU24350B1 (en) 5-HETEROARYL DERIVATIVES-4-phenyl-4,5-dihydro-pyrrolo (3,4-c) pyrazol-6-ONA active as inhibitors of BET
BR112015022191A2 (en) heteroaryl compounds, their use and composition comprising
GT201500312A (en) Sulfamoilpirrolamida derivatives and their use as medicaments for the treatment of hepatitis b
BR112015020389A2 (en) carbazole compounds useful as inhibitors bromodomain
TWI654997B (en) Lipid formulations for the delivery of therapeutic agents
UY34698A (en) pharmaceutical combinations comprising an analogue of thionucleotides
DOP2016000094A (en) Compounds derived pyridyl fused bicyclic ring like FGFR4 inhibitors.
CL2015002164A1 (en) combined formulation of two antiviral compuesos.
CR20150326A (en) Autotaxin inhibitors
CO7190242A2 (en) Nuclear transport modulators and uses thereof
CL2015000295A1 (en) Compounds derived alquilpirimidina; pharmaceutical composition that comprises; use for the treatment of viral infections and other diseases.
BR112015031903A2 (en) compound, pharmaceutically acceptable salt of the compound, pharmaceutical composition and use of a compound
CO7350624A2 (en) Inhibitors of Bruton tyrosine kinase
CL2014003136A1 (en) New diazaespirocicloalcanos and azaespirocicloalcanos; pharmaceutical composition containing them and uses.
BR112015013095A2 (en) cannula to minimize the dilution of nitric oxide during dose delivery.
BR112015020941A2 (en) use of pyrazolopyrimidine derivatives for the treatment of disorders related to pi3kdelta
CL2016002132A1 (en) Use of an amount of laquinimod, used to prepare a medicament for treating a human patient afflicted with multiple sclerosis or presenting a clinically isolated syndrome; a package, an amount of laquinimod and a pharmaceutical composition thereof.
BR112015025464A2 (en) coagonistas the GLP-1 receptor / glucagon stable, long for medical use